Prompt assessment of WST11-VTP outcome using luciferase transfected tumors enables second treatment and increase in overall therapeutic rate

被引:18
作者
Fleshker, Shimrit [1 ]
Preise, Dina [1 ]
Kalchenko, Vyacheslav [1 ]
Scherz, Avigdor [2 ]
Salomon, Yoram [1 ]
机构
[1] Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel
[2] Weizmann Inst Sci, Dept Plant Sci, IL-76100 Rehovot, Israel
关键词
D O I
10.1111/j.1751-1097.2008.00340.x
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
This study hypothesized that success rate assessment of vascular targeted photodynamic therapy (VTP) of solid tumors 24 h post-treatment may allow prompt administration of a second treatment in case of failure, increasing the overall success rate. Here, we show that treatment of luciferase transfected CT26-luc mouse colon carcinoma tumors in BALB/c mice by VTP with WST11 (a Pd-bacteriochlorophyll-based photosensitizer) allows fast assessment of treatment success 24 h post-treatment, using bioluminescence imaging (BLI). WST11-VTP was found to abolish luciferin bioluminescence in the treated tumors resulting in two types of responses. One, comprising 75% of the mice, signified successful outcome, presenting neither BLI signal nor tumor regrowth (24 h-90 days post-VTP). The second (the remaining 25% of the mice) signified treatment failure, presenting various levels of BLI signal with subsequent tumor regrowth (24 h-90 days). Consequently, the mice that failed the first treatment were treated again. We show that treatment success rate in both VTP sessions was identical and that the cumulative success rate of the treatment increased from 75% to over 90%. These results therefore, present a fast method of assessing VTP outcome and support the feasibility of successive multiple treatments with these sensitizers in the clinical arena. The presented methodology can also be helpful in future preclinical studies, and expedite the development of VTP drugs.
引用
收藏
页码:1231 / 1237
页数:7
相关论文
共 43 条
[1]   Targeting of the vascular system of solid tumours by photodynamic therapy (PDT) [J].
Abels, C .
PHOTOCHEMICAL & PHOTOBIOLOGICAL SCIENCES, 2004, 3 (08) :765-771
[2]  
Ackroyd R, 2001, PHOTOCHEM PHOTOBIOL, V74, P656, DOI 10.1562/0031-8655(2001)074<0656:THOPAP>2.0.CO
[3]  
2
[4]   Positron emission tomography imaging of tumor response after photodynamic therapy [J].
Bérard, V ;
Lecomte, R ;
van Lier, JE .
JOURNAL OF ENVIRONMENTAL PATHOLOGY TOXICOLOGY AND ONCOLOGY, 2006, 25 (1-2) :239-249
[5]   Novel water-soluble bacteriochlorophyll derivatives for vascular-targeted photodynamic therapy: Synthesis, solubility, phototoxicity and the effect of serum proteins [J].
Brandis, A ;
Mazor, O ;
Neumark, E ;
Rosenbach-Belkin, V ;
Salomon, Y ;
Scherz, A .
PHOTOCHEMISTRY AND PHOTOBIOLOGY, 2005, 81 (04) :983-993
[6]   Tumor hypoxia at the micro-regional level: clinical relevance and predictive value of exogenous and endogenous hypoxic cell markers [J].
Bussink, J ;
Kaanders, JHAM ;
van der Kogel, AJ .
RADIOTHERAPY AND ONCOLOGY, 2003, 67 (01) :3-15
[7]   Modification of tumor blood flow: Current status and future directions [J].
Chaplin, DJ ;
Hill, SA ;
Bell, KM ;
Tozer, GM .
SEMINARS IN RADIATION ONCOLOGY, 1998, 8 (03) :151-163
[8]   Blood flow dynamics after photodynamic therapy with verteporfin in the RIF-1 tumor [J].
Chen, B ;
Pogue, BW ;
Goodwin, IA ;
O'Hara, JA ;
Wilmot, CM ;
Hutchins, JE ;
Hoopes, PJ ;
Hasan, T .
RADIATION RESEARCH, 2003, 160 (04) :452-459
[9]   Intermittent blood flow in solid tumours - an under-appreciated source of 'drug resistance' [J].
Durand, RE .
CANCER AND METASTASIS REVIEWS, 2001, 20 (1-2) :57-61
[10]  
Gillies Robert J., 1999, Neoplasia (New York), V1, P197, DOI 10.1038/sj.neo.7900037